Aurealis Therapeutics is a Swiss-Finnish cell and gene therapy platform company.
Our multi-target scalable low COGS products, based on genetically engineered lactic acid bacteria, addresses unmet medical needs: Chronic wounds - diabetic foot ulcers, venous ulcers, pressure ulcers - deadly cancers - ovarian cancer, peritoneal carcinomatosis - inflammation.
Products, services, technology
Cooperation possibilities
Following a first licensing agreement for AUP-16 in China, we have an IND approval for a clinical study on diabetic foot ulcers to be conducted in China.
We are now aiming for a global licensing agreement - or multiple regional licensing - for AUP-16.
Some insights
We are a cell and gene therapy platform company with exciting phase-2 data at hand. Our multi-targeting products, based on genetically modified safe lactic acid bacteria, address broad unmet medical needs: Chronic wounds - diabetic foot ulcers, venous ulcer - ovarian cancer, inflammatory diseases.
With multi-targeting products addressing complex multi-factorial diseases, we create a better future for patients suffering from chronic wounds, cancers, and inflammatory diseases.
Our team has demonstrated business acumen, scientific expertise, and fundraising experience.
We have raised CHF 48 million to date. We have opened a CHF 35 million Series B round and are welcoming new investors.
Venture capital firms, private equity investors, family offices, and high‑net‑worth individuals.
